#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	4866	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2555	563.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1600	1600	C	690	C,T	582,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	4866	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2555	563.9	0	HET	.	.	.	C1201T,G	.	1201	1201	C	1617	1617	C	680	C,T,G	442,127,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7504	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3968	565.5	0	.	n	.	0	T695C	SNP	695	695	T	1299	1299	C	543	C	444	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7504	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3968	565.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1941	1941	A	731	A	617	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7504	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3968	565.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2575	2575	C	631	C	549	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7504	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3968	565.5	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3201	3201	T	644	T	544	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7504	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3968	565.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2649	2649	A	646	A	545	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	858	folP	852	852	100.0	folP.l6.c17.ctg.1	1796	142.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1168	1170	AGC	194;194;195	A;G;C	164;166;162	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1714	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3933	130.7	1	SNP	p	S91F	0	.	.	271	273	TCC	896	898	TCC	168;168;167	T;C;C	133;136;137	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1714	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3933	130.7	1	SNP	p	D95N	0	.	.	283	285	GAC	908	910	GAC	162;161;161	G,T;A;C	136,1;135;133	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1714	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3933	130.7	1	SNP	p	D95G	0	.	.	283	285	GAC	908	910	GAC	162;161;161	G,T;A;C	136,1;135;133	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	752	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1784	126.4	1	SNP	p	G45D	1	.	.	133	135	GAC	716	718	GAC	191;189;189	G;A,G;C	163;159,1;163	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	224	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1078	62.1	0	.	n	.	0	G15A	SNP	15	15	G	285	285	A	47	A	41	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1760	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3581	147.3	1	SNP	p	D86N	0	.	.	256	258	GAC	845	847	GAC	218;219;220	G;A;C	183;177;178	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1760	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3581	147.3	1	SNP	p	S87R	0	.	.	259	261	AGT	848	850	AGT	220;221;223	A;G,T;T	178;183,1;180	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1760	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3581	147.3	1	SNP	p	S87W	0	.	.	259	261	AGT	848	850	AGT	220;221;223	A;G,T;T	178;183,1;180	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1760	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3581	147.3	1	SNP	p	S87I	0	.	.	259	261	AGT	848	850	AGT	220;221;223	A;G,T;T	178;183,1;180	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1760	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3581	147.3	1	SNP	p	S88P	0	.	.	262	264	TCC	851	853	TCC	222;224;225	T;C;C	181;186;188	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1532	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2890	158.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1666	1668	GGC	181;181;180	G,A;G;C	154,1;156;155	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.47.001	penA.47.001	1	1	27	1396	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2820	148.3	1	SNP	p	A311V	0	.	.	931	933	GCC	1454	1456	GCC	183;182;180	G;C;C,A	148;149;148,1	penA.47.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1396	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2820	148.3	1	SNP	p	I312M	1	.	.	934	936	ATG	1457	1459	ATG	180;180;180	A;T;G	155;153;152	penA.47.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1396	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2820	148.3	1	SNP	p	V316T	1	.	.	946	948	ACC	1469	1471	ACC	175;176;176	A;C;C	151;147;153	penA.47.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1396	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2820	148.3	1	SNP	p	T316P	0	.	.	946	948	ACC	1469	1471	ACC	175;176;176	A;C;C	151;147;153	penA.47.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1396	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2820	148.3	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1970	1972	ACC	226;227;226	A;C,A;C	183;179,1;184	penA.47.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1396	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2820	148.3	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2024	2026	GCG	228;230;231	G,T;C,A,T;G,C	189,1;191,1,1;188,1	penA.47.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1396	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2820	148.3	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2024	2026	GCG	228;230;231	G,T;C,A,T;G,C	189,1;191,1,1;188,1	penA.47.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1396	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2820	148.3	1	SNP	p	G542S	0	.	.	1624	1626	GGC	2147	2149	GGC	228;229;229	G;G;C	189;191;187	penA.47.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1396	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2820	148.3	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2156	2158	GGC	228;227;226	G;G;C	186;189;192	penA.47.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1396	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2820	148.3	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2174	2176	CCG	228;228;227	C;C;G	192;193;187	penA.47.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1716	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3449	149.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1796	1798	CTG	178;178;179	C,T;T;G	141,1;143;148	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	974	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2181	133.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	760	760	C	148	C	120	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1222	1224	AAT	14;14;13	A;A;T	10;10;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1225	1227	AAT	13;13;13	A;A;T	9;8;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1249	1251	GCA	11;11;11	G;C;A	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1272	1274	GTA	10;10;10	G;T;A	8;7;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1278	1280	AAC	10;10;10	A;A;C	7;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1282	1286	TGGCG	10;10;10;10;10	T;G;G;C;G	8;7;7;8;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1288	1290	GCT	10;10;10	G;C;T	7;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1348	1350	TTA	7;7;7	T;T;A	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1393	1395	CAT	7;7;7	C;A;T	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1396	1398	AGT	7;7;7	A;G;T	6;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	294	90.6	porB1a.l15.c4.ctg.1	1491	18.3	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1405	1407	TAC	7;7;7	T;A;C	7;7;7	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	888	porB1b	1035	1035	98.09	porB1b.l15.c4.ctg.1	1889	138.3	0	.	p	.	0	H39L	NONSYN	115	117	CAT	618	620	CTT	180;179;179	C;T;T	152;148;150	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	888	porB1b	1035	1035	98.09	porB1b.l15.c4.ctg.1	1889	138.3	0	.	p	.	0	G46D	NONSYN	136	138	GGC	639	641	GAC	184;184;185	G;A;C	154;158;159	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	888	porB1b	1035	1035	98.09	porB1b.l15.c4.ctg.1	1889	138.3	0	.	p	.	0	E48K	NONSYN	142	144	GAA	645	647	AAA	184;184;185	A;A,G;A	157;152,1;158	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	888	porB1b	1035	1035	98.09	porB1b.l15.c4.ctg.1	1889	138.3	0	.	p	.	0	R143G	NONSYN	427	429	AGA	930	932	GGA	164;164;164	G;G;A	145;144;147	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	888	porB1b	1035	1035	98.09	porB1b.l15.c4.ctg.1	1889	138.3	0	.	p	.	0	S175T	NONSYN	523	525	TCA	1026	1028	ACA	169;172;172	A;C;A	151;150;151	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	888	porB1b	1035	1035	98.09	porB1b.l15.c4.ctg.1	1889	138.3	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1134	1134	T	186	T	152	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	888	porB1b	1035	1035	98.09	porB1b.l15.c4.ctg.1	1889	138.3	1	SNP	p	G120K	0	.	.	358	360	GGT	861	863	GGT	163;163;161	G;G,A;T	139;143,1;138	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	888	porB1b	1035	1035	98.09	porB1b.l15.c4.ctg.1	1889	138.3	1	SNP	p	A121N	0	.	.	361	363	GCC	864	866	GCC	161;161;161	G;C;C	139;135;137	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	888	porB1b	1035	1035	98.09	porB1b.l15.c4.ctg.1	1889	138.3	1	SNP	p	A121D	0	.	.	361	363	GCC	864	866	GCC	161;161;161	G;C;C	139;135;137	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3114	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5318	175.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2253	2255	AAT	183;183;184	A;A,G;T	156;162,1;156	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	504	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1379	108.9	1	SNP	p	V57M	1	.	.	169	171	ATG	684	686	ATG	207;207;207	A;T;G	170;171;172	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
